Real world outcomes of patients with relapsed/refractory prolymphocytic progression of CLL and splenic B-cell lymphoma/leukaemia with prominent nucleoli and the role of novel agents

This study will be an international multicentre retrospective study of patients with r/r prolymphocytic progression of CLL/SLL and SBLPN.

Update 20 July 2023 – Ongoing data collection at 4 sites (SCGH, FSH, PMCC, Brisbane site), Awaiting application at SCGH for RGS/HREC approval once pathway established, Ongoing discussion with additional sites to see if another few sites might be interested in participating.

Update 24 November 2023 – Sites have data, waiting on approval to get DTA’s completed

Update 17 February 2025 –  on hold until ethics & consent issues sorted.